OUP has injected follow-on funding into Palladio, creators of a drug for autosomal dominant polycystic kidney disease.
US-based kidney disease drug developer Palladio Biosciences closed a $20m series B round on Friday involving spinout-focused investment firm Osage University Partners.
Samsara BioCapital led the round, which also involved pharmaceutical firm Roche through its corporate venturing unit, Roche Venture Fund, as well as corporate-backed venture firm Medicxi.
Founded in 2015, Palladio Biosciences is progressing a clinical-stage drug called lixivaptan for autosomal dominant polycystic kidney disease (ADPKD), an inherited cause of kidney failure symptomised by the appearance…
